Family History of Age-Related Macular Degeneration and Genetics Predict Progression to Advanced Age-Related Macular Degeneration Adjusting for Macular Status, Demographic, and Lifestyle Factors.


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
11 2023
Historique:
received: 27 01 2023
revised: 16 06 2023
accepted: 16 06 2023
medline: 23 10 2023
pubmed: 13 7 2023
entrez: 12 7 2023
Statut: ppublish

Résumé

To determine if a family history of age-related macular degeneration (AMD) and genetic variants identify eyes at higher risk for progression to advanced AMD (AAMD), after controlling for baseline demographics, behavioral factors, and macular status. Prospective, longitudinal cohort study. Eyes were classified using the Age-Related Eye Disease Study severity scale. Non-genetic and genetic predictors for progression to AAMD, geographic atrophy, and neovascular disease were evaluated. Cox proportional hazards models using the eye as the unit of analysis were used to calculate hazard ratios (HRs), accounting for correlated data. Discrimination between progressing and non-progressing eyes was assessed using C-statistics and net reclassification improvement (NRI). Among 4910 eyes, 863 progressed to AAMD over 12 years. Baseline AMD severity scale and status of the fellow eye were important predictors; genes provided additional discrimination. A family history of AMD also independently predicted progression after accounting for genetic and other covariates: 1 family member versus none (HR 1.21 [95% confidence interval {CI} 1.02-1.43]; P = 0.03); ≥2 family members versus none (HR 1.55 [95% CI 1.26-1.90]; P < 0.001). A composite risk score calculated using β estimates of both non-genetic and significant genetic factors predicted progression to AAMD (HR 5.57; 90 Genetic variants and family history provided additional discrimination for predicting progression to AAMD, after accounting for baseline macular status and other covariates.

Identifiants

pubmed: 37437830
pii: S0002-9394(23)00250-7
doi: 10.1016/j.ajo.2023.06.017
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-86

Subventions

Organisme : NEI NIH HHS
ID : R01 EY011309
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY028602
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY022445
Pays : United States

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Johanna M Seddon (JM)

From the Department of Ophthalmology and Visual Sciences (J.M.S., D.D.), University of Massachusetts Chan Medical School, Worcester, Massachusetts. Electronic address: johanna_seddon@yahoo.com.

Dikha De (D)

From the Department of Ophthalmology and Visual Sciences (J.M.S., D.D.), University of Massachusetts Chan Medical School, Worcester, Massachusetts.

Bernard Rosner (B)

Department of Medicine (B.R.), Channing Division of Network Medicine, Harvard Medical School, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH